HistoIndex, a Singapore-based company developing imaging solutions for biological tissues, raised SGD9M in funding.
The round was led by OCBC with participation from ZIG Ventures and SEEDS Capital.
The company intends to use the funds to expand operations and its R$D efforts.
Founded in 2010, and led by CEO Dr.Ā Gideon Ho, HistoIndex provides stain-free and automated imaging solutions for visualizing and quantifying fibrosis in biological tissues. By combining biophotonic technology with AI-based analysis, it provides innovative tools to improve the assessment of fibrosis changes and drug efficacy.
Its digital pathology solutions are currently used in accelerating clinical research, expediting pharmaceutical drug development, and transforming medical standards.
The company has recently launched its first laboratory developed test (LDT), FibroSIGHT, now available for order in the US, whichĀ is designed to empower clinicians with liver fibrosis assessment.
FinSMEs
05/05/2025